Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Oncology

• Publication date

  2010-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdq248PMID 20494962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer : results from Japan Multinational Trial Organization LC00-03

  2010cited by this paper
• Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03

  2009cited by this paper
• Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

  2009cited by this paper
• Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.

  2009cited by this paper
• Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.

  2009influential reference
• Weekly paclitaxel in the adjuvant treatment of breast cancer.

  2008cited by this paper
• S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

  2008influential reference
• Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma

  2007cited by this paper
• A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).

  2007influential reference
• Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer

  2006influential reference
• Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

  2005cited by this paper
• How to calculate the dose of chemotherapy

  2002cited by this paper
• Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

  1999cited by this paper
• A Southwest Oncology Group study

  1993cited by this paper
• A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer.

  1992cited by this paper
• A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas.

  1992cited by this paper
• Dose‐response and dose‐survival advantage for high versus low‐dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer a southwest oncology group study

  1984cited by this paper

• Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study

  2025cites this paper
• Impact of TAS-102 dose reduction on severe neutropenia and survival outcomes in patients with metastatic colorectal cancer and prior chemotherapy-induced neutropenia.

  2025cites this paper
• Developing a machine-learning model to enable treatment selection for neoadjuvant chemotherapy for esophageal cancer

  2025cites this paper
• A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer

  2024cites this paper
• Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

  2024cites this paper
• Nanoparticle Albumin‑Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis

  2023cites this paper
• Влияние токсичности на объем проведения адъювантной химиотерапии

  2023cites this paper
• A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

  2023cites this paper
• Chemotherapy-Induced Neutropenia as a Prognostic Factor in Patients With Advanced Epithelial Ovarian Carcinoma

  2023cites this paper
• Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

  2022cites this paper
• Neutrophil Extracellular Traps in Cancer Therapy Resistance

  2022cites this paper
• Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study

  2022cites this paper
• Chemotherapy dose per kilogram lean body mass increased dose-limiting toxicity event in male head and neck cancer with taxane and platinum-based induction therapy

  2022cites this paper
• Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects

  2022cites this paper
• Leukocyte kinetics during the first cycle of chemotherapy predicts the outcome of patients with metastatic colorectal cancer and previous resection of the primary tumor

  2021cites this paper
• Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.

  2021cites this paper
• Current Advances and Outlook in Gastric Cancer Chemoresistance: A Review.

  2021cites this paper
• Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients’ outcome

  2021cites this paper
• Reduction of derived neutrophil-to-lymphocyte ratio after four weeks predicts the outcome of patients receiving second-line chemotherapy for metastatic colorectal cancer

  2020cites this paper
• Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX

  2020cites this paper
• Influence of preoperative chemotherapy-induced leukopenia on survival in patients with esophageal squamous cell carcinoma: exploratory analysis of JCOG9907

  2020cites this paper
• Meta-Analysis of Paclitaxel-Based Chemotherapy Combined With Traditional Chinese Medicines for Gastric Cancer Treatment

  2020cites this paper
• Effects of paclitaxel and resveratrol on blood characteristics in rabbits

  2020cites this paper
• Association between Severe Neutropenia Induced by Ramucirumab Plus Paclitaxel Combination Therapy and Overall Survival in Advanced Gastric Cancer

  2019cites this paper
• Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO‐04 randomized phase 3 rectal cancer trial

  2019cites this paper
• Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients

  2018cites this paper
• Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel

  2018cites this paper
• Timing of chemotherapy‐induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first‐line chemotherapy with oxaliplatin and capecitabine: a retrospective study

  2018cites this paper
• Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients

  2017cites this paper
• Prognostic value of chemotherapy-induced neutropenia in advanced gastric cancer patients undergoing first-line chemotherapy with DCF: a retrospective study

  2017cites this paper
• Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.

  2017cites this paper
• Severe neutropenia: a prognosticator in patients with advanced/recurrent colorectal cancer under oral trifluridine-tipiracil (TAS-102) chemotherapy.

  2017cites this paper
• Hematologic Adverse Effects following Systemic Chemotherapy

  2017cites this paper
• Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer

  2017cites this paper
• Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination

  2017cites this paper
• Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer

  2016cites this paper
• Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

  2016cites this paper
• The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma

  2016cites this paper
• Neutropenia as a prognostic factor and safety of second-line therapy with S-1 for advanced or recurrent pancreatic cancer.

  2016cites this paper
• Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma

  2016cites this paper
• Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.

  2016cites this paper
• Safety of an oral anticancer agent (trifluridine/tipiracil combination tablet) in patients with advanced and recurrent colorectal cancer.

  2016cites this paper
• Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial

  2016cites this paper
• Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial.

  2016cites this paper
• Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.

  2015cites this paper
• Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma

  2015cites this paper
• The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.

  2014cites this paper
• Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.

  2014cites this paper
• GALNT14 genotype, α-fetoprotein and therapeutic side effects predict post-chemotherapy survival in patients with advanced hepatocellular carcinoma.

  2014cites this paper
• Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.

  2014cites this paper
• Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection.

  2014cites this paper
• Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer.

  2014cites this paper
• Effect of the weekly administration of liposome-Paclitaxel combined with s-1 on advanced gastric cancer.

  2014cites this paper
• Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

  2014cites this paper
• Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer

  2013influential citation
• Association of chemotherapy-induced leucopenia with treatment outcomes in advanced non-small-cell lung cancer cases receiving the NP regimen.

  2012cites this paper
• Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context.

  2012cites this paper
• Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

  2011cites this paper
• Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy

  2011cites this paper
• Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer

  2011cites this paper
• Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin–5-Fluorouracil–Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963)

  2011influential citation
• Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

  2011cites this paper
• Randomized phase II study comparing dose escalated weekly paclitaxel vs. standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.

  2011cites this paper